Vascular endothelial dysfunction in patients with newly diagnosed type 2 diabetes and effects of 2-year and 5-year multifactorial intervention

Echocardiography

Volumn 28, Issue 10, 2011, Pages 1133-1140

  Tian, Jing ^a   Wen, Yanling ^a   Yan, Li ^a   Cheng, Hua ^a   Yang, Haiyun ^a   Wang, Jingfeng ^a   Kozman, Hani ^b   Villarreal, Daniel ^b   Liu, Kan ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

brachial artery flow mediated dilation; endothelium independent dilatation; multifactorial intervention; type 2 diabetes; vascular endothelial dysfunction

Indexed keywords

ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GLIMEPIRIDE; METFORMIN; ROSIGLITAZONE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BRACHIAL ARTERY FLOW MEDIATED VASODILATATION; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM INDEPENDENT DILATATION; FEMALE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; VASCULAR ENDOTHELIAL DYSFUNCTION;

CHINA; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; ULTRASONOGRAPHY; VENTRICULAR DYSFUNCTION;

EID: 81155148119     PISSN: 07422822     EISSN: 15408175     Source Type: Journal    
DOI: 10.1111/j.1540-8175.2011.01514.x     Document Type: Article

References (33)

1. Vinik AI, Vinik E,: Prevention of the complications of diabetes. Am J Manag Care 2003; 9 (3 Suppl): S63-S80;quiz S81-64. (Pubitemid 36401621)
2. Selvin E, Marinopoulos S, Berkenblit G, et al,: Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421-431.
3. Gerstein HC, Pogue J, Mann JF, et al,: The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: A prospective epidemiological analysis. Diabetologia 2005; 48: 1749-1755. (Pubitemid 41317828)
4. Aguilar D, Deswal A, Ramasubbu K, et al,: Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. Am J Cardiol 2010; 105: 373-377.
5. Interventions and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes. N Engl J Med 2000; 342: 381-389.
6. Writing Team For The Diabetes Control And Complications Trial/Epidemiology Of Diabetes Interventions And Complications Research Group: Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290: 2159-2167.
7. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
8. UK Prospective Diabetes Study (UKPDS) Group: Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
9. Patel A, MacMahon S, Chalmers J, et al,: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572. (Pubitemid 351831357)
10. Duckworth W, Abraira C, Moritz T, et al,: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
11. Goff DC, Gerstein HC, Ginsberg HN, et al,: Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: Current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007; 99: 4i-20i.
12. Hashemi M, Hoseinbalam M, Khazaei M,: Long-term effect of enhanced external counterpulsation on endothelial function in the patients with intractable angina. Heart Lung Circ 2008; 17: 383-387.
13. Suzuki T, Hirata K, Elkind MS, et al,: Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: The Northern Manhattan Study (NOMAS). Am Heart J 2008; 156: 405-410.
14. American Diabetes Association: Position statement: Standards of medical care patients with diabetes mellitus. Diabetes 2002; 25: S33-S49.
15. Gaede P, Vedel P, Larsen N, et al,: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393. (Pubitemid 36159355)
16. Gaede P, Lund-Andersen H, Parving HH, et al,: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591. (Pubitemid 351214285)
17. Anderson TJ,: Prognostic significance of brachial flow-mediated vasodilation. Circulation 2007; 115: 2373-2375. (Pubitemid 46717957)
18. Cozma A, Orasan O, Sampelean D, et al,: Endothelial dysfunction in metabolic syndrome. Rom J Intern Med 2009; 47: 133-140.
19. Wilson PW, D'Agostino RB, Parise H, et al,: Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066-3072. (Pubitemid 43113437)
20. Fioretto P, Steffes MW, Sutherland DE, et al,: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339: 69-75. (Pubitemid 28304880)
21. Nathan DM, Lachin J, Cleary P, et al,: Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003; 348: 2294-2303. (Pubitemid 36638103)
22. Altiere RJ, Kiritsy-Roy JA, Catravas JD,: Acetylcholine-induced contractions in isolated rabbit pulmonary arteries: Role of thromboxane A2. J Pharmacol Exp Ther 1986; 236: 535-541. (Pubitemid 16184254)
23. Katusic ZS, Vanhoutte PM,: Superoxide anion is an endothelium-derived contracting factor. Am J Physiol 1989; 257: H33-H37.
24. Gryglewski RJ, Palmer RM, Moncada S,: Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986; 320: 454-456. (Pubitemid 16097810)
25. Engler MM, Engler MB, Malloy MJ, et al,: Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation 2003; 108: 1059-1063. (Pubitemid 37071514)
26. Kinlay S, Behrendt D, Fang JC, et al,: Long-term effect of combined vitamins E and C on coronary and peripheral endothelial function. J Am Coll Cardiol 2004; 43: 629-634. (Pubitemid 38229536)
27. Zhang Q, Chang Z, Yang J, Wang Q,: Antiatherogenic property of triterpenoids-enriched extract from the aerial parts of Salvia miltiorrhiza. Phytother Res 2008; 22: 1040-1045.
28. Ling S, Dai A, Guo Z, et al,: A preparation of herbal medicine Salvia miltiorrhiza reduces expression of intercellular adhesion molecule-1 and development of atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2008; 51: 38-44.
29. Meyer MF, Lieps D, Schatz H, et al,: Influence of the duration of type 2 diabetes on early functional and morphological markers of atherosclerosis compared to the impact of coexisting classic cardiovascular risk factors. Exp Clin Endocrinol Diabetes 2008; 116: 298-304. (Pubitemid 351798740)
30. Tsuchiya K, Nakayama C, Iwashima F, et al,: Advanced endothelial dysfunction in diabetic patients with multiple risk factors: Importance of insulin resistance. J Atheroscler Thromb 2007; 14: 303-309.
31. Chan K, Chui SH, Wong DY, et al,: Protective effects of Danshensu from the aqueous extract of Salvia miltiorrhiza (Danshen) against homocysteine-induced endothelial dysfunction. Life Sci 2004; 75: 3157-3171. (Pubitemid 39361173)
32. Sieveking DP, Woo KS, Fung KP, et al,: Chinese herbs Danshen and Gegen modulate key early atherogenic events in vitro. Int J Cardiol 2005; 105: 40-45. (Pubitemid 41408528)
33. Zhao L, Gaudry L, Dunkley S, et al,: Modulation of platelet and leucocyte function by a Chinese herbal formulation as compared with conventional antiplatelet agents. Platelets 2008; 19: 24-31. (Pubitemid 351171557)